Liu et al., have also demonstrated that SphK2 is overexpressed in NSCLC, and SphK2 knockdown inhibited proliferation and enhanced gefitinib sensitivity in NSCLC cells [16]. The gene discussed is SPHK2; the disease is non-small cell lung carcinoma.